VolitionRx Partners with Hologic to Expand Access to Epigenetic Testing Services

VolitionRx Ltd. has announced a strategic co-marketing and services agreement with Hologic Diagenode, a division of Hologic Inc., to promote Volition's Nu.Q® Discover service to pharmaceutical developers and research scientists. The partnership represents a significant expansion opportunity for Volition's epigenetic testing platform, which offers a comprehensive suite of assays for rapid epigenetic profiling across various stages of drug development including disease model development, preclinical testing, and clinical studies.

Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, emphasized the strategic importance of this collaboration, noting that it marks a significant milestone for the Nu.Q® Discover program. The agreement is expected to substantially increase customer access to Volition's proprietary epigenetic assays, which target an estimated total addressable market of $200 million annually. This partnership strengthens Volition's position in the growing pharmaco-epigenetics market while supporting revenue growth objectives through expanded market reach and service capabilities.

Raphael Werding, Head of Life Sciences at Hologic, expressed enthusiasm about incorporating Nu.Q® Discover into Hologic's service portfolio. Hologic brings extensive experience across multiple disease areas including oncology, cardiovascular conditions, neurodegenerative disorders, and immunology. The company believes nucleosome quantification technology can provide valuable biological insights to biotech, pharmaceutical, and academic clients engaged in therapeutic development across these disease categories.

The initial agreement spans one year with provisions for potential expansion into an exclusive provider arrangement based on performance and mutual agreement on additional terms. This collaboration leverages Hologic's established customer relationships and technical expertise while providing Volition with enhanced market penetration capabilities for its epigenetic testing services. The partnership represents a strategic alignment between Volition's innovative epigenetic technologies and Hologic's established presence in the life sciences research and diagnostic markets.

For additional information about Volition's corporate activities and technology platform, interested parties can visit the company's official website at https://www.Volition.com. The collaboration with Hologic represents a significant step in Volition's strategy to establish its Nu.Q® technology as a standard tool in pharmaceutical research and development workflows, potentially accelerating drug discovery and development timelines through advanced epigenetic profiling capabilities.